ClinicalTrials.gg
CompletedNCT06903156Updated Dec 12, 2025

Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)

A Phase 2 interventional study of Mexidol and Placebo in Primary Open-Angle Glaucoma (POAG), sponsored by Pharmasoft. Completed at 7 sites in Russia. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Pharmasoft · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Nov 2021, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Study summary

The present trial is planned to investigate and identify the best dosage of investigational drugs with respect to the treatment of open-angle glaucoma. Therefore, multiple dose regimens of the investigational drug versus placebo drug are anticipated.

Read the detailed description

Glaucoma is a widespread group of diseases, which are united by disorders of the hydrodynamics of the eye with increased intraocular pressure (IOP), development of glaucoma optic neuropathy (GON) and corresponding irreversible changes in the optic nerve and visual fields.

The number of glaucoma patients worldwide ranges from 60.5 to 105 million, more than 1 million glaucoma patients have been identified in Russia, but it is assumed that the true number of patients is twice as high. According to epidemiological analysis, primary open-angle glaucoma (POAG) is the most common glaucoma worldwide, accounting for 75% to 90% of all primary glaucoma.

The active substance of Mexidol (ethylmethylhydroxypyridine succinate) has a multitarget effect on a number of links in the pathogenesis of POAG and is characterised by a high degree of safety, which corresponds to the concept of multimodal and modulating therapy of GON in POAG.

02

Conditions studied

  • Primary Open-Angle Glaucoma (POAG)

Keywords

  • Glaucoma
  • Primary Open-Angle Glaucoma (POAG)
  • Glaucomatous Optic Neuropathy (GON)
  • Mitochondrial Dysfunction
  • Neuroprotection
  • Retiniprotection
  • Mexidol
  • Ethylmethylhydroxypyridine Succinate
03

In context

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 102 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Pharmasoft is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes aged 35 to 75 years inclusive.
  • Diagnosis of primary open-angle glaucoma stage II or III in both eyes.
  • Intraocular pressure (IOP) compliance with ""target level"": tonometric IOP \<21 mmHg in stage II, \<19 mmHg in stage III, in both eyes.
  • The patient's willingness and ability to fulfil the requirements of the protocol throughout the trial.
  • Patients who signed to participate in the trial.
  • For women with preserved , a negative pregnancy test and agreement to use adequate methods throughout the trial.
  • For men, agreement to adhere to adequate contraceptive methods for the duration of trial participation.

Exclusion criteria

Exclusion Criteria:

  • Individual intolerance or to any of the components of the medicinal products according to anamnesis data.
  • Administration of nootropic, vasoactive drugs, neuroprotectants, antioxidants, metabolic drugs for 30 days prior to randomisation.
  • The need to use medications that are prohibited in this trial.
  • Primary open-angle glaucoma stage I or IV in at least one eye.
  • Closed-angle glaucoma of at least one eye.
  • The only eye.
  • Diagnosis of primary open-angle glaucoma stage II or III in one eye only.
  • Visual acuity less than 0.1 (with correction) in at least one eye.
  • Presence of an active infectious-inflammatory process in at least one eye.
  • Low reliability of SAP results in at least one eye due to the patient's condition/disease: presence of 20% or more false positive and/or false negative errors, large amplitude and frequency of gaze direction deviations.
  • The "mean deviation" (MD) score for static automatic perimetry (SAP) is -20 decibels or worse in at least one eye.
  • Surgical and/or laser interventions on at least one eyeball within 3 months prior to inclusion in the trial.
  • Significant opacities of the optical media in at least one eye, preventing assessment of the efficacy of therapy, including: severe scarring of the cornea, cataracts, consequences of uveitis.
  • Retinal detachment in at least one eye.
  • Thrombosis of a central retinal vein or artery in at least one eye.
  • Myopia with a length of the anteroposterior axis of the eyeball greater than 26 mm in at least one eye.
  • Diabetic retinopathy and other eye conditions that may affect the assessment of therapy efficacy.
  • Presence of a history or finding of pathology on screening, including but not limited to those listed below: unstable angina pectoris within 3 months before inclusion in the trial; myocardial infarction within 3 months prior to inclusion in the trial; acute heart failure; severe arrhythmia requiring treatment with class Ia, Ib, Ic or III antiarrhythmic drugs; decompensation of chronic heart failure (according to the classification) within 3 months before inclusion in the trial; uncontrolled arterial hypertension with systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg at screening; brain injury, stroke or within 6 months prior to screening; occlusive blood vessel diseases; stenosing blood vessel diseases resulting in significant ischaemia of the relevant blood supply area; metabolic disorders, including severe renal insufficiency ( less than 30 ml/min); severe hepatic insufficiency ( or AST level is at least 2 times higher than the values); malignant diseases of any localization with duration of remission less than 5 years according to anamnesis; II or III degree respiratory failure; community-acquired pneumonia within 6 months prior to inclusion in the trial; severe and/or uncontrolled endocrine and metabolic disorders requiring continuous medication; type 1 diabetes mellitus; type 2 diabetes mellitus, with a disease duration of 5 or more years; gastrointestinal disorders in the phase of relapse or exacerbation and requiring continuous medication.
  • Positive serological reactions for infections at screening: (antibodies to HIV-1/2); (surface antigen); (antibodies to hepatitis C virus antigens); Syphilis (antibodies to Treponema pallidum).
  • Presence of other ophthalmological, neurological, otolaryngological or systemic diseases that may be the cause of optic nerve damage.
  • The presence of any other pathology that, in the opinion of the investigator, is a to the patient's participation in the trial (i.e. may adversely affect the patient's condition if he or she participates in the trial), may interfere with the conduct of the trial procedures, or affect the ability to interpret the results of the trial. In case of doubt, the investigator should consult with the trial medical monitor.
  • Signs of a first detected disease/pathology at screening.
  • Positive rapid test for IgM antibodies to SARS-CoV-2 and/or positive SARS-CoV-2 RNA using nucleic acid amplification techniques
  • Current or history (two years prior to screening) of alcoholism, drug abuse, drug dependence and/or substance abuse.
  • Mental, physical and other reasons that make it impossible to adequately assess one's behaviour and correctly comply with the conditions of the trial protocol, including a history of mental illness.
  • Lack of willingness to co-operate on the part of the patient.
  • Pregnancy and breastfeeding period. A positive pregnancy test in women of .
  • Patient participation in another clinical trial within the last 30 days.
  • Patient refusal to continue participation in the trial.
  • A decision by the Investigator or Sponsor to exclude a patient from the trial due to a significant protocol deviation/protocol violation.
  • A serious adverse event (SAE) or an adverse event that does not meet the criteria for seriousness, for which, in the opinion of the Investigator, further participation in the trial may be detrimental to the health or well-being of the patient, or for which withdrawal of the investigational therapy is necessary.
  • The need for procedures and/or adjunctive therapy not authorized by the protocol of this trial.
  • Allergic reaction or individual intolerance to the investigational drugs, requiring their cancellation.
  • Non-compliance with the therapy regime (patient's adherence to treatment with tablet form of the drug goes beyond 80%-120%, parenteral therapy - 100%), non-adherence (loss of contact with the patient with subsequent non-appearance at the visit, violation of visit dates, etc.).
  • Need for modification of topical hypotensive therapy.
  • Occurrence during the trial of conditions/diseases specified in the inclusion criteria.
  • Any patient condition that, in the reasonable judgement of the investigator, requires the patient to be excluded from the trial.
  • Erroneous inclusion.
  • Positive pregnancy test in a trial participant.
  • Positive rapid test for IgM antibodies to SARS-CoV-2 and/or positive SARS-CoV-2 RNA using nucleic acid amplification techniques.
  • Erroneous unblinding of trial subject's treatment group.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Active comparator
    Mexidol High

    High dose of Mexidol (Mexidol IV 500 mg 1 time a day for 14 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 90 days) and standard therapy

    Drug: Mexidol

  • Active comparator
    Mexidol Low

    Low dose of Mexidol (Mexidol IV 100 mg 1 time a day for 14 days, then Mexidol 125 mg 1 tablet 3 times a day for 90 days) and standard therapy

    Drug: Mexidol

  • Placebo comparator
    Placebo

    Placebo and standard therapy according to a scheme similar to Mexidol groups

    Other: Placebo

Interventions

  • Neuroretinoprotector

    Also known as: Ethylmethylhydroxypyridine Succinate

  • OtherPlacebo

    Placebo therapy

06

What researchers measure

Primary outcomes

  1. Mean change in mean deviation (MD) in static automated perimetry (SAP) at the end of the course of therapy vs. baseline

    Time frame: Day 104

Secondary outcomes

  1. Mean change in the mean deviation (MD) of static automated perimetry (SAP) 14, 45 and 75 days from the start of therapy vs. baseline

    Time frame: 14, 45 and 75 days

  2. Mean change in pattern standard deviation (PSD) at static automated perimetry (SAP) 14, 45, 75 and 104 days from the start of therapy vs. baseline

    Time frame: 14, 45, 75 and 104 days

  3. Change in the number of relative scotomas (first and second order), number of absolute scotomas after 14, 45, 75 and 104 days from the start of therapy vs. baseline

    Time frame: 14, 45, 75 and 104 days

  4. Mean change in visual acuity according to visometry without correction after 14, 45, 75 and 104 days from the start of therapy vs. baseline

    Time frame: 14, 45, 75 and 104 days

  5. Mean change in visual acuity according to visometry with correction after 14, 45, 75 and 104 days from the start of therapy vs. baseline

    Time frame: 14, 45, 75 and 104 days

  6. Mean change in the value of the threshold of electrical sensitivity of the optic nerve after 14, 45, 75 and 104 days from the beginning of therapy vs. baseline

    Time frame: 14, 45, 75 and 104 days

  7. Mean change in the value of the electrical lability of the optic nerve after 14, 45, 75 and 104 days from the start of therapy vs. baseline level

    Time frame: 14, 45, 75 and 104 days

  8. Dynamics of changes severity according to optical coherence tomography data after 14, 45, 75 and 104 days from the beginning of therapy in comparison with the initial level

    Time frame: 14, 45, 75 and 104 days

  9. Dynamics of the severity of changes according to Heidelberg retinal tomography data after 14, 45, 75 and 104 days from the start of therapy vs. baseline

    Time frame: 14, 45, 75 and 104 days

07

Study locations

7 sites
  • Kirov Regional State Budgetary Healthcare Institution "Kirov Clinical Ophthalmological Hospital"
    Kirov, 610047, Russia
  • Federal State Budgetary Educational Institution of Higher Education "Moscow State Medical and Dental Institute named after A.I. Evdokimov" of the Ministry of Health of the RF
    Moscow, 127473, Russia
  • Federal State Autonomous Institution "Intersectoral Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Health of the RF
    Moscow, 127486, Russia
  • Budgetary healthcare institution of the Omsk region "V.P. Vyhodtsev Clinical Ophthalmological Hospital"
    Omsk, 644024, Russia
  • Saint Petersburg State Budgetary Healthcare Institution "State Hospital No. 40 of the Kurortny District"
    Saint Petersburg, 197706, Russia
  • Private healthcare institution "Clinical hospital "RZhD-Medicine" of the city of Saratov"
    Saratov, 410004, Russia
  • State Budgetary Institution of Healthcare of the Yaroslavl Region "Clinical Hospital No. 2"
    Yaroslavl, 150030, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Sep 2023, 21 months.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 21 months is above that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 30, 2025
StartActual
Nov 15, 2021
Primary completionActual
Sep 7, 2023
CompletionActual
Sep 7, 2023
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06903156
Lead sponsor
Pharmasoft
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Nov 15, 2021
Primary completion
Sep 7, 2023
Completion
Sep 7, 2023
Last update
Dec 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emoxypine succinate

Start the discussion